MX2020006944A - Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. - Google Patents
Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer.Info
- Publication number
- MX2020006944A MX2020006944A MX2020006944A MX2020006944A MX2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A MX 2020006944 A MX2020006944 A MX 2020006944A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- patient
- ipsc
- prophylactic
- therapeutic treatment
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000000069 prophylactic effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008672 reprogramming Effects 0.000 abstract 1
- 210000001082 somatic cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En una modalidad, la solicitud describe un método para el tratamiento del cáncer en un paciente, el método comprende una vacunación del paciente con una vacuna, en donde la vacuna comprende una cantidad efectiva de células madre pluripotentes de mamífero obtenidas a partir de una fuente embrionaria, u obtenidas por la reprogramación de células somáticas a partir del paciente, en donde la vacunación comprende el paso de administrar células madre pluripotentes de mamífero al paciente en necesidad de esto; y formulaciones de vacuna para uso en el tratamiento de cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862612826P | 2018-01-02 | 2018-01-02 | |
| PCT/US2019/012003 WO2019136038A1 (en) | 2018-01-02 | 2019-01-01 | Ipsc-based vaccine as a prophylactic and therapeutic treatment for cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006944A true MX2020006944A (es) | 2020-11-09 |
Family
ID=65444317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006944A MX2020006944A (es) | 2018-01-02 | 2019-01-01 | Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11298380B2 (es) |
| EP (1) | EP3720482A1 (es) |
| JP (2) | JP2021509122A (es) |
| KR (1) | KR20200140238A (es) |
| CN (2) | CN111936161B (es) |
| AU (1) | AU2018399641A1 (es) |
| CA (1) | CA3087254A1 (es) |
| MX (1) | MX2020006944A (es) |
| SG (1) | SG11202006160RA (es) |
| WO (1) | WO2019136038A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200131301A (ko) * | 2018-03-13 | 2020-11-23 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 세포 노화의 역전을 위한 일시적 세포 재프로그래밍 |
| JP2022546578A (ja) * | 2019-09-04 | 2022-11-04 | ブイセル セラピューティックス，インコーポレイテッド | 癌を処置するためのワクチンおよびストレスリプログラミングによるその作製方法 |
| EP4149525A4 (en) * | 2020-05-15 | 2024-08-28 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES |
| EP4346886A1 (en) | 2021-06-01 | 2024-04-10 | Khloris Biosciences, Inc. | Induced pluripotent stem cell-based cancer vaccines |
| CN113440606A (zh) * | 2021-06-02 | 2021-09-28 | 深圳市罗湖区人民医院 | 特异性多能干细胞肿瘤疫苗及其制备方法与应用 |
| KR20240082339A (ko) * | 2021-08-13 | 2024-06-10 | 클로리스 바이오사이언시스 인코포레이티드 | 암에 대한 예방적 및 치료적 치료로서 ipsc-기반 백신 |
| EP4619015A1 (en) * | 2022-11-15 | 2025-09-24 | The Board of Trustees of the Leland Stanford Junior University | Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine |
| CN120661647A (zh) * | 2024-03-19 | 2025-09-19 | 国家纳米科学中心 | 一种免疫组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000009075A2 (en) | 1998-08-14 | 2000-02-24 | Galenica Pharmaceuticals, Inc. | Chemically modified saponins and the use thereof as adjuvants |
| DE10012370A1 (de) | 2000-03-14 | 2001-09-27 | Chiron Behring Gmbh & Co | Adjuvans für Vakzinen |
| US20050158329A1 (en) | 2004-01-21 | 2005-07-21 | Ghosh Swapan K. | Novel phytol derived immunoadjuvants and their use in vaccine formulations |
| CA2504451A1 (en) | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| CA2596920C (en) | 2005-01-28 | 2015-05-05 | North-West University | Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines |
| EP2925332A4 (en) * | 2012-08-20 | 2016-12-21 | Boris Markosian | PLACENTAL IMP THERAPY AGAINST CANCER |
| US20160024469A1 (en) | 2013-07-29 | 2016-01-28 | Allan Yang Wu | Non-conventional Cellular Based Immunotherapy |
| US10801041B2 (en) | 2015-11-18 | 2020-10-13 | Orbis Health Solutions, Llc | T7 alpha viral vector system |
| CN116376812A (zh) | 2016-05-25 | 2023-07-04 | 国家医疗保健研究所 | 治疗癌症的方法和组合物 |
-
2019
- 2019-01-01 WO PCT/US2019/012003 patent/WO2019136038A1/en not_active Ceased
- 2019-01-01 CA CA3087254A patent/CA3087254A1/en active Pending
- 2019-01-01 SG SG11202006160RA patent/SG11202006160RA/en unknown
- 2019-01-01 KR KR1020207022233A patent/KR20200140238A/ko not_active Ceased
- 2019-01-01 US US16/237,705 patent/US11298380B2/en active Active
- 2019-01-01 JP JP2020555746A patent/JP2021509122A/ja active Pending
- 2019-01-01 EP EP19705835.7A patent/EP3720482A1/en active Pending
- 2019-01-01 CN CN201980008834.8A patent/CN111936161B/zh active Active
- 2019-01-01 MX MX2020006944A patent/MX2020006944A/es unknown
- 2019-01-01 AU AU2018399641A patent/AU2018399641A1/en not_active Abandoned
- 2019-01-01 CN CN202410710283.2A patent/CN118512582A/zh active Pending
-
2023
- 2023-11-06 JP JP2023189481A patent/JP2024026069A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3087254A1 (en) | 2019-07-11 |
| AU2018399641A1 (en) | 2020-07-16 |
| SG11202006160RA (en) | 2020-07-29 |
| JP2024026069A (ja) | 2024-02-28 |
| CN111936161B (zh) | 2024-06-18 |
| WO2019136038A1 (en) | 2019-07-11 |
| US11298380B2 (en) | 2022-04-12 |
| US20190290697A1 (en) | 2019-09-26 |
| JP2021509122A (ja) | 2021-03-18 |
| CN118512582A (zh) | 2024-08-20 |
| KR20200140238A (ko) | 2020-12-15 |
| CN111936161A (zh) | 2020-11-13 |
| EP3720482A1 (en) | 2020-10-14 |
| WO2019136038A4 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020006944A (es) | Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. | |
| MX2026002469A (es) | Nuevas moleculas de acido nucleico artificiales | |
| EP4477662A3 (en) | Nucleic acid molecules and uses thereof | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| AR106582A1 (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos | |
| MX395585B (es) | Composiciones producidas por microorganismos con actividad estimuladora sobre las plantas | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| EP4403138A3 (en) | Device and method with reduced pacemaker rate in heart valve replacement | |
| MX2022009155A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| EP4484443A3 (en) | Materials and methods for treatment of friedreich ataxia and other related disorders | |
| WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| MX2021005245A (es) | Composiciones de oligosacaridos y metodos de uso de las mismas. | |
| EP4420722A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
| EP4295906A3 (en) | Treatment of restenosis using temsirolimus | |
| MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| EP4520312A3 (en) | Therapeutic gas infused cosmetic and methods of infusion | |
| MX2019014867A (es) | Metodo para tratar un efecto secundario de la inmunoterapia. | |
| WO2018158542A8 (fr) | Cellules souches mesenchymateuses issues de la gelée de wharton pour le traitement du sepsis | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| EA202090990A1 (ru) | Системы и способы получения в-клеток генетически модифицированных для экспрессии выбранных антител |